News
NVO
85.00
-17.83%
-18.44
Trending stocks in bearish pre-holiday week for U.S. stock market
Seeking Alpha · 11h ago
Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Seeking Alpha · 12h ago
Novo Nordisk bleeding prevention injection for hemophilia granted FDA nod
Seeking Alpha · 14h ago
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
The Motley Fool · 15h ago
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
The Motley Fool · 17h ago
Lazard International Equity Select Portfolio Q3 2024 Commentary
Seeking Alpha · 20h ago
NOVO NORDISK A/S - TRIAL SHOWS 86% REDUCTION IN BLEEDS WITH ALHEMO PROPHYLAXIS
Reuters · 1d ago
FDA APPROVES ALHEMO® INJECTION AS ONCE-DAILY PROPHYLACTIC TREATMENT TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER WITH HEMOPHILIA A OR B WITH INHIBITORS
Reuters · 1d ago
NOVO NORDISK A/S - COMMON ADVERSE REACTIONS INCLUDE INJECTION SITE REACTIONS AND URTICARIA
Reuters · 1d ago
Why Viking Therapeutics Tumbled by More Than 10% This Week
The Motley Fool · 1d ago
FDA: APPROVES ALHEMO DRUG TO PREVENT/REDUCE FREQUENCY OF BLEEDING EPISODES FOR PATIENTS WITH HEMOPHILIA A WITH INHIBITORS/HEMOPHILIA B WITH INHIBITORS
Reuters · 1d ago
Stocks Rally on Hopes for More Rate Cuts
The Wall Street Journal · 1d ago
BUZZ-US stocks weekly: Snow squall
Reuters · 1d ago
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla
The Wall Street Journal · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 1d ago
Novo Nordisk price target lowered to $105 from $155 at TD Cowen
TipRanks · 1d ago
TD Cowen Sticks to Their Buy Rating for Novo Nordisk (NVO)
TipRanks · 1d ago
Dow Surges Over 600 Points, Gold Jumps 1.5%
Benzinga · 1d ago
Wall Street Rallies On Soft Inflation Data, Bonds Rebound, Travel Stocks Surge: What's Driving Markets Friday?
Benzinga · 1d ago
What's Going On With Amgen Stock On Friday?
Benzinga · 1d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.